Business
NFL Biosciences Significantly Raises Its Efficacy Targets for Smoking Cessation
MONTPELLIER, France, January 26, 2026--Regulatory News: NFL Biosciences SA (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addiction, announces today that it is significantly raising the efficacy targets for its drug candidates in smoking cessation.
About this update from Nfl Biosciences Sa
[{"type":"list","items":[{"val":[{"type":"text","content":"In-depth understanding of the mechanism of action of its drug candidates based on new data","length":90,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":90,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Enhanced clinical development strategy based on these advances, targeting clinical efficiencies superior to those of current treatments","length":135,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":135,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Identification of a novel mechanism of action in smoking cessation, paving the way for continued clinical development of NFL-101 targeting a subpopulation of smokers with an increased response potential","length":202,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":202,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Introduction of NFL-102, a drug candidate with an extended mechanism of action, intended for the general smoking population to achieve superior efficacy compared to standard treatments across the entire population","length":213,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":213,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"NFL-101 acts primarily on neuroinflammation, while NFL-102 targets the central mechanisms of smoking cessation by modulating key signaling pathways, in particular CREB, recognized as a major regulator of tobacco addiction","length":221,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":221,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Unchanged projected clinical development timelines and reduced costs for confirmatory studies","length":93,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":93,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Active search for strategic partners for Phase 3 financing","length":58,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":58,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Extension of intellectual property rights with a new patent application extending protection until 2047 and expanding to other addictions beyond tobacco and...